Global Hirudin Market Growth 2025-2031

The global Hirudin market size is predicted to grow from US$ 4131 million in 2025 to US$ 4996 million in 2031; it is expected to grow at a CAGR of 3.2% from 2025 to 2031.

This report studies the Hirudin market. Hirudin is a naturally occurring peptide in the salivary glands of medicinal leeches (such as Hirudo medicinalis) that has a blood anticoagulant property. Hirudin is the most potent natural inhibitor of thrombin. Hirudin (hirudin) is a Leech (Leech) and salivary glands have been extracted from a variety of active ingredients in the activity of the most significant and most studied ingredients, which is 65-66 amino acids from the small molecules of protein (peptide) . Hirudin have strong inhibitory effect on thrombin is the strongest so far found in the natural specific inhibitor of thrombin. Animal experiments and clinical studies have shown that hirudin can be effective anticoagulant, antithrombotic, and prevent thrombin-catalyzed activation of coagulation factors and platelet reactions and blood stasis phenomenon further. In addition, it also inhibited thrombin-induced fibroblast proliferation, and thrombin stimulation of endothelial cells. Compared with heparin, which not only use less, do not cause bleeding, is not dependent on endogenous cofactor; and heparin have caused the risk of bleeding, disseminated intravascular coagulation in the pathogenesis of antithrombin III are reduced This will limit the efficacy of heparin, using leeches will have good results.

Global Hirudin key players include Pfizer, Teva Pharmaceutical, The Medicines Company, SALUBRIS, DUOPUTAI, etc. Global top five manufacturers hold a share about 20%. North America is the largest market, with a share about 30%, followed by Europe, with a share about 20 percent. In terms of product, Natural Hirudin is the largest segment, with a share about 55%. And in terms of application, the largest application is Thrombosis Disease, followed by Tumor Disease, etc.

LP Information, Inc. (LPI) ' newest research report, the “Hirudin Industry Forecast” looks at past sales and reviews total world Hirudin sales in 2024, providing a comprehensive analysis by region and market sector of projected Hirudin sales for 2025 through 2031. With Hirudin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hirudin industry.

This Insight Report provides a comprehensive analysis of the global Hirudin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hirudin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Hirudin market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hirudin and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hirudin.

This report presents a comprehensive overview, market shares, and growth opportunities of Hirudin market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Natural Hirudin
Recombinant Hirudin

Segmentation by Application:
Thrombosis Disease
Tumor Disease
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
The Medicines Company
Keyken
Minapharm
Abbott
SALUBRIS
Pfizer, Inc
Teva Pharmaceutical Industries Ltd
DUOPUTAI
Pentapharm

Key Questions Addressed in this Report

What is the 10-year outlook for the global Hirudin market?

What factors are driving Hirudin market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Hirudin market opportunities vary by end market size?

How does Hirudin break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.